Verona Pharma plc (NASDAQ:VRNA) CEO Sells $116,200.00 in Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 23,240 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $5.00, for a total transaction of $116,200.00. Following the sale, the chief executive officer now owns 15,177,512 shares of the company’s stock, valued at $75,887,560. This trade represents a 0.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

David Zaccardelli also recently made the following trade(s):

• On Monday, December 2nd, David Zaccardelli sold 3,200 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total transaction of $16,000.00.
• On Friday, November 29th, David Zaccardelli sold 98,888 shares of Verona Pharma stock. The stock was sold at an average price of $5.01, for a total transaction of $495,428.88.
• On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total transaction of $12,000.00.
• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The stock was sold at an average price of $4.39, for a total transaction of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $1,076,533.92.

Verona Pharma Price Performance

Shares of NASDAQ:VRNA opened at $39.85 on Thursday. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The firm’s 50-day moving average is $35.26 and its two-hundred day moving average is $25.89. Verona Pharma plc has a 1 year low of $11.39 and a 1 year high of $40.76.

Verona Pharma (NASDAQ:VRNA) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The business had revenue of $5.62 million for the quarter, compared to the consensus estimate of $2.31 million. During the same quarter in the prior year, the company earned ($0.18) EPS. Analysts anticipate that Verona Pharma plc will post -2.11 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on VRNA shares. HC Wainwright lifted their target price on shares of Verona Pharma from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group lifted their target price on shares of Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Truist Financial boosted their price target on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Finally, Wells Fargo & Company boosted their price target on shares of Verona Pharma from $50.00 to $64.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $43.83.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Eventide Asset Management LLC increased its position in shares of Verona Pharma by 359.6% in the third quarter. Eventide Asset Management LLC now owns 2,425,846 shares of the company’s stock valued at $69,792,000 after buying an additional 1,898,065 shares in the last quarter. Maverick Capital Ltd. lifted its stake in shares of Verona Pharma by 74.2% in the 2nd quarter. Maverick Capital Ltd. now owns 3,092,807 shares of the company’s stock valued at $44,722,000 after purchasing an additional 1,316,998 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in shares of Verona Pharma in the 3rd quarter valued at about $31,966,000. Candriam S.C.A. acquired a new position in Verona Pharma during the 2nd quarter worth approximately $11,177,000. Finally, Jennison Associates LLC lifted its position in Verona Pharma by 54.3% during the 3rd quarter. Jennison Associates LLC now owns 1,740,886 shares of the company’s stock worth $50,085,000 after acquiring an additional 612,854 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.